Michel Ghilezan - Concepedia

Author

Michel Ghilezan

Beaumont Hospital, Royal Oak

Also Known As

M Ghilezan, M. Ghilezan, M.I. Ghilezan, MICHEL GHILEZAN, Michel Ghilezan, Michel I. Ghilezan

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Beaumont Hospital, Royal Oak 21st Century Oncology (United States)Oakland University

About

Michel Ghilezan is an author at Beaumont Hospital, Royal Oak specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	836
2	Health Sciences	4	4	206
3	Radiation Medicine	3	3	243
4	Engineering	1	1	161
5	Endocrinology	1	1	31

Michel Ghilezan

Publications

Citations

H-Index

Page 1

	Year	Citations
High-Dose-Rate Monotherapy: Safe and Effective Brachytherapy for Patients With Localized Prostate Cancer D. Jeffrey Demanes, Alvaro A. Martinez, Michel Ghilezan, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyUrologyHigh-dose-rate MonotherapyRadiation TherapyEffective Brachytherapy	2011	167
Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery Michel Ghilezan, Di Yan, Jian Liang, International Journal of Radiation OncologyBiologyPhysics Adaptive RadiotherapyEngineeringRadiation TherapyMedical ImagingMedicine	2004	161
High-Dose-Rate Prostate Brachytherapy Alvaro A. Martinez, J. Demanes, Carlos Vargas, American Journal of Clinical Oncology	2010	159
Analysis of Treatment Efficacy, Cosmesis, and Toxicity Using the MammoSite Breast Brachytherapy Catheter to Deliver Accelerated Partial-Breast Irradiation: The William Beaumont Hospital Experience K. Chao, Frank A. Vicini, Michelle Wallace, International Journal of Radiation OncologyBiologyPhysics Toxicity UsingRadiation MedicineBreast OncologyRadiation TherapyRadiobiology	2007	135
High-Dose-Rate Brachytherapy as Monotherapy Delivered in Two Fractions Within One Day for Favorable/Intermediate-Risk Prostate Cancer: Preliminary Toxicity Data Michel Ghilezan, Alvaro A. Martinez, Gary Gustason, International Journal of Radiation OncologyBiologyPhysics UrologyRadiation TherapyFavorable/intermediate-risk Prostate CancerMedicineBrachytherapy	2011	91
Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension? K. Chao, Neal S. Goldstein, Di Yan, International Journal of Radiation OncologyBiologyPhysics UrologySurgical OncologyPerineural InvasionGenitourinary CancerMedicine	2006	84
Lack of Benefit for the Addition of Androgen Deprivation Therapy to Dose-Escalated Radiotherapy in the Treatment of Intermediate- and High-Risk Prostate Cancer Daniel Krauss, Larry L. Kestin, Hong Ye, International Journal of Radiation OncologyBiologyPhysics UrologyRadiation MedicineHigh-risk Prostate CancerRadiation TherapyMedicine	2010	73
A NEW MODEL USING NUMBER OF NEEDLES AND ANDROGEN DEPRIVATION TO PREDICT CHRONIC URINARY TOXICITY FOR HIGH OR LOW DOSE RATE PROSTATE BRACHYTHERAPY Carlos Vargas, Michel Ghilezan, Mitchell Hollander, The Journal of Urology	2005	42
Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ Sean S. Park, Inga S. Grills, Peter Y. Chen, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyRadiation MedicineBreast OncologyRadiation TherapyMedicine	2010	35
Prognostic Significance of Neuroendocrine Differentiation in Patients With Gleason Score 8–10 Prostate Cancer Treated With Primary Radiotherapy Daniel Krauss, Sylvia Hayek, Mitual Amin, International Journal of Radiation OncologyBiologyPhysics Endocrine OncologyUrologySurgical OncologyMedicineNeuroendocrine Disorder	2011	31

Page 1